Organon & Co. (NYSE: OGN)’s stock price has decreased by -1.96 compared to its previous closing price of 21.95. However, the company has seen a -9.12% decrease in its stock price over the last five trading sessions.
Is It Worth Investing in Organon & Co. (NYSE: OGN) Right Now?
Organon & Co. (NYSE: OGN) has a price-to-earnings ratio that is above its average at 5.99x. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The average price predicted for Organon & Co. (OGN) by analysts is $32.88, which is $11.36 above the current market price. The public float for OGN is 254.22M, and at present, short sellers hold a 2.86% of that float. On March 16, 2023, the average trading volume of OGN was 2.18M shares.
OGN’s Market Performance
The stock of Organon & Co. (OGN) has seen a -9.12% decrease in the past week, with a -27.00% drop in the past month, and a -21.97% fall in the past quarter. The volatility ratio for the week is 3.20%, and the volatility levels for the past 30 days are at 3.78% for OGN. The simple moving average for the last 20 days is -13.86% for OGN stock, with a simple moving average of -25.47% for the last 200 days.
Analysts’ Opinion of OGN
Many brokerage firms have already submitted their reports for OGN stocks, with BofA Securities repeating the rating for OGN by listing it as a “Underperform.” The predicted price for OGN in the upcoming period, according to BofA Securities is $25 based on the research report published on October 14th of the previous year 2022.
Piper Sandler, on the other hand, stated in their research note that they expect to see OGN reach a price target of $34, previously predicting the price at $37. The rating they have provided for OGN stocks is “Overweight” according to the report published on September 06th, 2022.
BofA Securities gave a rating of “Neutral” to OGN, setting the target price at $37 in the report published on August 05th of the previous year.
OGN Trading at -23.38% from the 50-Day Moving Average
After a stumble in the market that brought OGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.95% of loss for the given period.
Volatility was left at 3.78%, however, over the last 30 days, the volatility rate increased by 3.20%, as shares sank -26.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.95% lower at present.
During the last 5 trading sessions, OGN fell by -9.12%, which changed the moving average for the period of 200-days by -44.19% in comparison to the 20-day moving average, which settled at $24.60. In addition, Organon & Co. saw -22.95% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for OGN
Current profitability levels for the company are sitting at:
- +27.84 for the present operating margin
- +63.07 for the gross margin
The net margin for Organon & Co. stands at +14.85. Equity return is now at value -84.40, with 8.60 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.56.
Conclusion
To sum up, Organon & Co. (OGN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
